E. Davis

发表

The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress

P. Dent, S. Grant, M. Rahmani, 2007, Molecular and Cellular Biology.

Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation*

P. Dent, S. Grant, M. Rahmani, 2005, Journal of Biological Chemistry.

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

R. Advani, P. Greenberg, B. Sikic, 1999, Blood.

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis.

S. Devlin, A. Scaradavou, S. Giralt, 2019, Blood advances.

Racial disparities in access to alternative donor allografts persist in the era of “donors for all”

M. Perales, James W. Young, A. Scaradavou, 2021, Blood advances.

Guidelines for Cord Blood Unit Selection.

J. Wagner, E. Shpall, A. Scaradavou, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose and 8-allele HLA-Match by Patient Ancestry.

S. Devlin, A. Scaradavou, E. Davis, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).

R. Advani, P. Greenberg, B. Sikic, 1999, Advances in experimental medicine and biology.

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

R. Advani, P. Greenberg, B. Sikic, 1999 .

meeting held in San Diego, CA, December 1997. 833 (Valspodar) : Presented in part at the American Society of Hematology Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

P. Greenberg, M. Tallman, E. Paietta, 2013 .

Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

R. Advani, P. Greenberg, B. Sikic, 1999 .

Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection.

M. Perales, S. Devlin, A. Scaradavou, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.

S. Devlin, K. Hsu, S. Giralt, 2021, Blood advances.

Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units

A. Scaradavou, E. Davis, J. Barker, 2020, Bone Marrow Transplantation.

Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine

R. Advani, P. Greenberg, B. Sikic, 1998 .

C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis

Wencai Ma, R. Orlowski, J. Hou, 2017, Science Signaling.

Targeting B-cell receptor signaling: changing the paradigm.

E. Davis, N. Fowler, 2013, Hematology. American Society of Hematology. Education Program.

Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.

R. Fisher, T. Grogan, D. Catovsky, 2005, Cancer research.

Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma

Ash A. Alizadeh, A. Newman, R. Advani, 2016 .

An optimized search prognosis tool to predict 8/8 HLA-allele matched unrelated donor procurement.

A. Scaradavou, J. Flynn, E. Davis, 2023, Transplantation and cellular therapy.

Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation.

S. Devlin, A. Scaradavou, S. Giralt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Analysis of Disparities in Time to Allogeneic Transplantation in Adults with Acute Myelogenous Leukemia.

M. Perales, S. Devlin, James W. Young, 2022, Blood advances.

Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and health care delivery

A. Scaradavou, E. Davis, W. Fingrut, 2022, Blood advances.

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Michael R. Green, T. McDonnell, Y. Oki, 2019, Blood.

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Michael R. Green, Michael L. Wang, S. Parmar, 2019, Blood.

Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

C. Flowers, D. Chihara, L. Fayad, 2021, Blood.

Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia

M. Perales, M. Tallman, S. Giralt, 2018 .

The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress

P. Dent, S. Grant, M. Rahmani, 2007 .